Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM and Opthea Sign Agreement

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
Agreement to manufacture Opthea’s lead product for eye disease.

DSM Pharmaceutical Products has announced that it has signed an agreement with Opthea Pty Ltd of Melbourne, Australia.

The contract covers process development and cGMP manufacture by DSM for Opthea's lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are involved in the progression of eye diseases.

This project represents an agreement for process development at DSM Biologics’ Groningen, The Netherlands, facility and manufacture at the newly established cGMP facility in Brisbane, Australia.

Opthea, a private 100% owned subsidiary of Circadian Technologies Limited (ASX: CIR; OTCQX: CKDXY), is developing its lead molecule OPT-302, previously known as VGX-300, initially for the treatment of “wet” (neovascular) age-related macular degeneration (wet AMD).

“Wet” (neovascular) age-related macular degeneration, or wet AMD, is a disease characterized by the loss of vision in the middle of the visual field caused by degeneration of the central portion of the retina (the macula).

Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, cause retinal degeneration and leads to severe and rapid loss of vision.

Dr. Megan Baldwin, CEO of Opthea said “We are pleased to announce our manufacturing agreement with DSM and to have the opportunity to work with their highly experienced and internationally recognized team. Opthea is excited to be able to progress our manufacturing program in a new state-of the-art facility within Australia and looks forward to further building on our strong relationship with DSM.”

Manja Bouman, President of DSM Biologics, commented “We are honored to be working with an innovative company such as Opthea, and apply our expertise to help them bring this novel biologic treatment to patients in need. We look forward to working together with our partner on this exciting project and support them in their further development of this important drug."

Queensland Minister for Science and Innovation, Ian Walker, has welcomed the deal signed by DSM Biologics and Melbourne-based Opthea today. “This is good news for Queensland and the deal is evidence of the growing reputation at a national and international level of the DSM facility with its experienced team, state-of-the-art equipment, its excellent manufacturing capability and its value for money proposition. These kinds of partnerships will be vital to the growth of this industry in Queensland.” Mr. Walker said.

DSM Biologics, a business unit of DSM Pharmaceutical Products, focuses on optimizing mammalian-based biopharmaceutical manufacturing through its unique set of technologies and expertise.

In addition to an R&D and manufacturing site in Groningen, The Netherlands, DSM has opened operations in Brisbane, Australia, with the support of the Government of Queensland and the Commonwealth of Australia.

The Brisbane facility is DSM's blueprint for its 'biologics plant of the future' for the production of biopharmaceuticals.

DSM's proprietary technologies drive down cost, processing times and capital requirements to meet market demand for developing affordable lifesaving medications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM Celebrates Opening of New cGMP Facility
DSM Pharmaceutical Products officially opens its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
Wednesday, October 30, 2013
DSM and DecImmune Therapeutics Sign Agreement
Agreement to develop N2 pathway blocking antibody.
Monday, April 22, 2013
DSM Announces Biologics Development and Manufacturing Agreement for Australian Facility
DSM has signed a biologics contract manufacturing agreement with Paranta Biosciences.
Thursday, October 25, 2012
DSM Announces South American Biologics Contract Manufacturing Agreement
DSM sign contract manufacturing agreement with RECEPTA Biopharma.
Tuesday, July 17, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!